Free Trial

Janux Therapeutics (JANX) SEC Filings & 10K Form

Janux Therapeutics logo
$45.35 +0.29 (+0.64%)
As of 01/14/2025 04:00 PM Eastern

Recent Janux Therapeutics SEC Filings

DateFilerForm TypeView
01/08/2025
7:00 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:11 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
7:00 PM
Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/03/2025
7:01 PM
Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
Form 3/A
01/03/2025
7:10 PM
Dobek Maria (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM
DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM
Janux Therapeutics (Issuer)
Robinson Byron (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM
Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM
Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
7:00 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
9:00 AM
Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
5:25 PM
Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2024
3:32 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
3:28 PM
Janux Therapeutics (Filer)
Form 424B5
12/03/2024
7:00 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
4:10 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/27/2024
7:00 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
3:24 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Janux Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:58 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
11/07/2024
6:08 PM
CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2024
6:09 PM
Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2024
3:23 PM
Janux Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
3:07 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:05 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
4:02 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:24 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:30 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:17 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:07 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/30/2024
6:30 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2024
3:46 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
4:28 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/25/2024
3:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:44 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:51 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
11:37 AM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
10/24/2024
4:53 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
4:04 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
3:15 PM
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
4:59 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:38 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:39 PM
Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G
10/23/2024
4:07 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
3:36 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2024
3:20 PM
Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:16 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/22/2024
3:17 PM
Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
10/21/2024
3:43 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
3:25 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
12:39 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
5:51 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
3:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:39 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:48 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
4:06 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:24 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:18 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
5:14 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:35 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:28 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:25 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:17 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:10 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
7:49 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2024
4:29 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
4:34 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
6:30 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
6:31 PM
DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
6:32 PM
Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
5:31 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
4:05 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:51 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:51 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:54 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:18 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:01 PM
Janux Therapeutics (Subject)
Meyer Andrew Hollman (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:05 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:35 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:13 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/16/2024
8:35 PM
Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
09/16/2024
8:41 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
09/13/2024
4:01 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
8:18 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
7:54 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
8:07 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
7:42 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
5:23 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
3:51 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
09/11/2024
10:20 AM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
09/10/2024
5:26 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
5:32 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
5:22 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
4:51 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
4:02 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2024
3:13 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
5:03 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
5:09 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
2:35 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:JANX) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners